{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-24-000683","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.845954+00:00","generated_at":"2026-06-03T07:57:19.691948+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RenovaroCube to acquire remaining 25% of Cyclomics for 100% ownership in cancer diagnostics","bullets":["RenovaroCube amends LOI to acquire full 100% ownership of Cyclomics (was 75%).","Deal strengthens AI-driven early cancer detection; combines CyclomicsSeq and OmniOmics 4th-gen tech.","Collaborations with Oxford Nanopore and Nvidia provide sequencing, supercomputing, and AI software.","Technology aims to detect a single ctDNA molecule in blood with nearly 100% accuracy.","RenovaroCube's Cube platform has over 3,600 biomarker panels for 13 cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-24-000683","json":"https://secwatch.observer/filing/0001731122-24-000683.json","markdown":"https://secwatch.observer/filing/0001731122-24-000683.md","text":"https://secwatch.observer/filing/0001731122-24-000683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000683/0001731122-24-000683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000683/e5618_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:57:19.691948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}